Notice of Availability for Exclusive, Non-Exclusive, or Partially-Exclusive Licensing of an Invention Concerning Antibody-Dependent Cellular Cytoxicity (ADCC)-Mediating Antibodies

---
identifier: "/us/fr/2013-30367"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Notice of Availability for Exclusive, Non-Exclusive, or Partially-Exclusive Licensing of an Invention Concerning Antibody-Dependent Cellular Cytoxicity (ADCC)-Mediating Antibodies"
title_number: 0
title_name: "Federal Register"
section_number: "2013-30367"
section_name: "Notice of Availability for Exclusive, Non-Exclusive, or Partially-Exclusive Licensing of an Invention Concerning Antibody-Dependent Cellular Cytoxicity (ADCC)-Mediating Antibodies"
positive_law: false
currency: "2013-12-20"
last_updated: "2013-12-20"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Defense Department"
document_number: "2013-30367"
document_type: "notice"
publication_date: "2013-12-20"
agencies:
  - "Defense Department"
  - "Army Department"
fr_citation: "78 FR 77107"
fr_volume: 78
fr_action: "Notice."
---


#  Notice of Availability for Exclusive, Non-Exclusive, or Partially-Exclusive Licensing of an Invention Concerning Antibody-Dependent Cellular Cytoxicity (ADCC)-Mediating Antibodies

**AGENCY:**

Department of the Army, DoD.

**ACTION:**

Notice.

**SUMMARY:**

Announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 61/762,543, entitled “Antibody-Dependent Cellular Cytoxicity (ADCC)-Mediating Antibodies,” filed on February 8, 2013. The United States Government, as represented by the Secretary of the Army, has rights to this invention.

**ADDRESSES:**

Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.

**FOR FURTHER INFORMATION CONTACT:**

For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619-6664, both at telefax (301) 619-5034.

**SUPPLEMENTARY INFORMATION:**

The invention relates to Antibody-Dependent cellular cytoxicity (ADCC)-mediating antibodies, and, in particular, to ADCC-mediating antibodies (and fragments thereof) suitable for use, for example, in reducing the risk of HIV-1 infection in a subject. The invention further relates to compositions comprising such antibodies or antibody fragments.

Brenda S. Bowen,

Army  Federal Register  Liaison Officer.